{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:57:20Z","timestamp":1776070640218,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["Gilead Sciences"],"award-info":[{"award-number":["Gilead Sciences"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["South African Medical Research Council"],"award-info":[{"award-number":["South African Medical Research Council"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10461-025-04952-z","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:56:13Z","timestamp":1763204173000},"page":"1097-1108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adherence to Oral HIV Pre-exposure Prophylaxis During Pregnancy and the Post-partum Period: Lessons Learned in an Open-Labelled Clinical Trial"],"prefix":"10.1007","volume":"30","clinical-trial-number":[{"clinical-trial-number":"nct03227731","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nondumiso","family":"Khoza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia C.","family":"Desmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1849-9631","authenticated-orcid":false,"given":"Dhayendre","family":"Moodley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"issue":"3","key":"4952_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S2055-6640(20)30492-1","volume":"1","author":"E Pool","year":"2015","unstructured":"Pool E, Youssef E, Fisher M. Oral PrEP for HIV prevention. It works. J Virus Erad. 2015;1(3):168\u201372.","journal-title":"J Virus Erad"},{"key":"4952_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399\u2013410.","journal-title":"N Engl J Med"},{"key":"4952_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1402269","volume":"372","author":"JM Marrazzo","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509\u201318.","journal-title":"N Engl J Med"},{"issue":"5","key":"4952_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1202614","volume":"367","author":"L Van Damme","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411\u201322.","journal-title":"N Engl J Med"},{"key":"4952_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-025-04741-8","author":"D Zeballos","year":"2025","unstructured":"Zeballos D, Guimar\u00e3es NS, Pereira M, Magno L, Dourado I. Performance of adherence measures for oral, Tenofovir-based HIV pre-exposure prophylaxis: a systematic review. AIDS Behav. 2025. https:\/\/doi.org\/10.1007\/s10461-025-04741-8.","journal-title":"AIDS Behav"},{"issue":"11","key":"4952_CR6","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1038\/s41591-023-02564-5","volume":"29","author":"M Moore","year":"2023","unstructured":"Moore M, Stansfield S, Donnell DJ, et al. Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence. Nat Med. 2023;29(11):2748\u201352.","journal-title":"Nat Med"},{"issue":"6","key":"4952_CR7","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s10461-010-9799-4","volume":"14","author":"JE Haberer","year":"2010","unstructured":"Haberer JE, Kahane J, Kigozi I, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340\u20136.","journal-title":"AIDS Behav"},{"issue":"12","key":"4952_CR8","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1007\/s10461-023-04111-2","volume":"27","author":"N Musinguzi","year":"2023","unstructured":"Musinguzi N, Ngure K, Bukusi EA, et al. Performance of multiple adherence measures for pre-exposure prophylaxis (PrEP) among young women in Kenya. AIDS Behav. 2023;27(12):3961\u20139.","journal-title":"AIDS Behav"},{"key":"4952_CR9","unstructured":"WHO. Technical brief: preventing HIV during pregnancy and breastfeeding in the context of PrEP. July, 2017. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255866\/WHO-HIV-2017.09-eng.pdf"},{"issue":"8","key":"4952_CR10","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/hiv.12252","volume":"16","author":"BM Best","year":"2015","unstructured":"Best BM, Burchett S, Li H, et al. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015;16(8):502\u201311.","journal-title":"HIV Med"},{"key":"4952_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/frph.2023.1224580","volume":"5","author":"RK Scott","year":"2023","unstructured":"Scott RK, Yu Y, Marzinke MA, Coleman JS, Hendrix CW, Bies R. Clinical trial simulation to evaluate tenofovir disoproxil fumarate\/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy. Front Reprod Health. 2023;5:1224580.","journal-title":"Front Reprod Health"},{"issue":"7","key":"4952_CR12","doi-asserted-by":"publisher","first-page":"e1893","DOI":"10.1093\/cid\/ciaa1872","volume":"73","author":"L Stranix-Chibanda","year":"2021","unstructured":"Stranix-Chibanda L, Anderson PL, Kacanek D, et al. Tenofovir diphosphate concentrations in dried blood spots from pregnant and postpartum adolescent and young women receiving daily observed Pre-exposure prophylaxis in Sub-Saharan Africa. Clin Infect Dis. 2021;73(7):e1893\u2013900.","journal-title":"Clin Infect Dis"},{"issue":"13","key":"4952_CR13","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1097\/QAD.0000000000001922","volume":"32","author":"M Pyra","year":"2018","unstructured":"Pyra M, Anderson PL, Hendrix CW, et al. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis. AIDS. 2018;32(13):1891\u20138.","journal-title":"AIDS"},{"key":"4952_CR14","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/QAI.0000000000001850","volume":"79","author":"J Pintye","year":"2018","unstructured":"Pintye J, Kinuthia J, Roberts DA, et al. Brief report: integration of PrEP services into routine antenatal and postnatal care: experiences from an implementation program in Western Kenya. J Acquir Immune Defic Syndr. 2018;79:590\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4952_CR15","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3018(19)30335-2","volume":"7","author":"J Kinuthia","year":"2020","unstructured":"Kinuthia J, Pintye J, Abuna F, et al. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in kenya: results from an implementation programme. Lancet HIV. 2020;7:e38\u201348.","journal-title":"Lancet HIV"},{"issue":"4","key":"4952_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/QAI.0000000000003586","volume":"98","author":"I Beesham","year":"2025","unstructured":"Beesham I, Jaggernath M, Kriel Y, et al. Longitudinal changes in tenofovir and tenofovir diphosphate concentrations among pregnant women using oral PrEP for HIV prevention: findings from Durban, South Africa. J Acquir Immune Defic Syndr. 2025;98(4):357\u201362.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"4952_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26044","volume":"25","author":"D Joseph Davey","year":"2022","unstructured":"Joseph Davey D, Nyemba DC, Castillo-Mancilla J, et al. Adherence challenges with daily oral pre-exposure prophylaxis during pregnancy and the postpartum period in South African women: a cohort study. J Int AIDS Soc. 2022;25(12):e26044.","journal-title":"J Int AIDS Soc"},{"key":"4952_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/frph.2023.1224474","volume":"5","author":"N Khadka","year":"2023","unstructured":"Khadka N, Gorbach PM, Nyemba DC, et al. Evaluating the use of oral pre-exposure prophylaxis among pregnant and postpartum adolescent girls and young women in Cape Town, South Africa. Front Reprod Health. 2023;5:1224474.","journal-title":"Front Reprod Health"},{"issue":"3","key":"4952_CR19","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2352-3018(22)00369-1","volume":"10","author":"D Moodley","year":"2023","unstructured":"Moodley D, Lombard C, Govender V, et al. Pregnancy and neonatal safety outcomes of timing of initiation of daily oral Tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial. Lancet HIV. 2023;10(3):e154\u201363.","journal-title":"Lancet HIV"},{"issue":"2","key":"4952_CR20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/aid.2012.0089","volume":"29","author":"JR Castillo-Mancilla","year":"2013","unstructured":"Castillo-Mancilla JR, Zheng JH, Rower JE, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29(2):384\u201390.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"4952_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11606-017-4260-2","volume":"33","author":"M Huang","year":"2018","unstructured":"Huang M, Liu W, Plomondon ME, Prochazka AV, Bessesen MT. High adherence to HIV pre-exposure prophylaxis among veterans. J Gen Intern Med. 2018;33(3):253\u20135.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"4952_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02168-20","volume":"65","author":"AC Eke","year":"2021","unstructured":"Eke AC, Shoji K, Best BM, et al. Population pharmacokinetics of tenofovir in pregnant and postpartum women using tenofovir disoproxil fumarate. Antimicrob Agents Chemother. 2021;65(3):e02168\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"4952_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0310861","volume":"19","author":"D Zeballos","year":"2024","unstructured":"Zeballos D, Magno L, Soares F, et al. Performance of indirect adherence measures for daily oral pre-exposure prophylaxis for HIV among adolescent men who have sex with men and transgender women in Brazil. PLoS One. 2024;19(12):e0310861.","journal-title":"PLoS One"},{"issue":"5","key":"4952_CR24","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/QAI.0000000000000216","volume":"66","author":"KR Amico","year":"2014","unstructured":"Amico KR, Marcus JL, McMahan V, et al. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr. 2014;66(5):530\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"4952_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/QAI.0000000000003309","volume":"95","author":"BH Chi","year":"2024","unstructured":"Chi BH, Saidi F, Graybill LA, et al. A patient-centered, combination intervention to support adherence to HIV pre-exposure prophylaxis during pregnancy and breastfeeding: a randomized pilot study in Malawi. J Acquir Immune Defic Syndr. 2024;95(1):42\u201351.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4952_CR26","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1097\/QAD.0000000000003617","volume":"37","author":"J Pintye","year":"2023","unstructured":"Pintye J, Kinuthia J, Abuna F, et al. HIV pre-exposure prophylaxis initiation, persistence, and adherence during pregnancy through the postpartum period. AIDS. 2023;37:1725\u201337.","journal-title":"AIDS"},{"issue":"3","key":"4952_CR27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/QAI.0000000000000158","volume":"66","author":"AL Corneli","year":"2014","unstructured":"Corneli AL, Deese J, Wang M, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2014;66(3):324\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"4952_CR28","doi-asserted-by":"publisher","first-page":"20642","DOI":"10.7448\/IAS.19.1.20642","volume":"19","author":"A van der Straten","year":"2016","unstructured":"van der Straten A, Brown ER, Marrazzo JM, et al. Divergent adherence estimates with Pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. J Int AIDS Soc. 2016;19(1):20642.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"4952_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10461-016-1609-1","volume":"21","author":"ET Montgomery","year":"2017","unstructured":"Montgomery ET, Mensch B, Musara P, et al. Misreporting of product adherence in the MTN-003\/VOICE trial for HIV prevention in Africa: participants\u2019 explanations for dishonesty. AIDS Behav. 2017;21(2):481\u201391.","journal-title":"AIDS Behav"},{"issue":"2","key":"4952_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab609","volume":"9","author":"DL Joseph Davey","year":"2021","unstructured":"Joseph Davey DL, Dovel K, Mvududu R, et al. Pre-exposure prophylaxis recent adherence with real-time adherence feedback and partner human immunodeficiency virus self-testing: a pilot trial among postpartum women. Open Forum Infect Dis. 2021;9(2):ofab609.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"4952_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10461-021-03374-x","volume":"26","author":"A Moran","year":"2022","unstructured":"Moran A, Mashele N, Mvududu R, et al. Maternal PrEP use in HIV-uninfected pregnant women in South Africa: role of stigma in PrEP initiation, retention and adherence. AIDS Behav. 2022;26(1):205\u201317.","journal-title":"AIDS Behav"},{"issue":"12","key":"4952_CR32","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1007\/s10461-021-03320-x","volume":"25","author":"DL Joseph Davey","year":"2021","unstructured":"Joseph Davey DL, Knight L, Markt-Maloney J, et al. I had made the decision, and no one was going to stop me -facilitators of PrEP adherence during pregnancy and postpartum in Cape Town, South Africa. AIDS Behav. 2021;25(12):3978\u201386.","journal-title":"AIDS Behav"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04952-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-025-04952-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04952-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:07:48Z","timestamp":1776067668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-025-04952-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4952"],"URL":"https:\/\/doi.org\/10.1007\/s10461-025-04952-z","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"assertion":[{"value":"24 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The parent study (CAP 016) was conducted in compliance with approval from the South African Health Products Regulatory Authorities (SAHPRA). This study was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC\/00003767\/2022).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human and Animal Participants"}},{"value":"All participants signed an informed consent that included study follow-up procedures and storage of specimens for future research. All laboratory specimens, evaluation forms, reports, and other records were identified only by a coded number to maintain subject confidentiality.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}